title: The low-density lipoprotein cholesterol-lowering effect of pravastatin and factors associated with achieving targeted low-density lipoprotein levels in an African-American population.
abstract: OBJECTIVE
  To describe the low-density lipoprotein cholesterol (LDL)-lowering effect of pravastatin in African-American patients and to identify factors associated with achieving National Cholesterol Education Program (NCEP)-defined target levels.
  
  
  METHODS
  Retrospectively defined cohort study.
  
  
  METHODS
  Large, government-owned, teaching hospital.
  
  
  METHODS
  Eighty-four African-American patients starting therapy with pravastatin in October-November 1997.
  
  
  METHODS
  None.
  
  
  RESULTS
  Whether or not target LDL concentrations were achieved was used to measure efficacy. Stepwise logistic regression identified the target LDL, baseline LDL, and baseline high-density lipoprotein cholesterol (HDL) as significant predictors of achieving the target. The proportion of patients achieving their target LDL when that target was below 160, below 130, and 100 mg/dl or below was 64%, 32%, and 13% (p=0.004), respectively. Medical record review identified the reasons for not achieving target as incorrect drug regimen, inadequate lipid monitoring, and noncompliance.
  
  
  CONCLUSIONS
  These results indicate that substantial numbers of patients receiving lipid-lowering therapy are not meeting NCEP-defined targets and that with increased drug monitoring and compliance, improvements in achieving NCEP target LDL levels could be realized.
authors.affiliation: Department of Pharmacy, Cook County Hospital, Chicago, Illinois, USA. cpang@uic.edu
authors.forename: P H
authors.initials: PH
authors.lastname: Chong
authors.forename: P J
authors.initials: PJ
authors.lastname: Tzallas-Pontikes
authors.forename: J D
authors.initials: JD
authors.lastname: Seeger
authors.forename: T D
authors.initials: TD
authors.lastname: Stamos
mesh_terms: D001741:Black or African American; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D044383:Black People; D008078:Cholesterol, LDL / Q000097:blood*; D015331:Cohort Studies; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D006937:Hypercholesterolemia / Q000097:blood / Q000188:drug therapy*; D008077:Lipoproteins, LDL / Q000097:blood*; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance; D017035:Pravastatin / Q000627:therapeutic use*; D012189:Retrospective Studies; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D000924:Anticholesteremic Agents; D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008077:Lipoproteins, LDL; D017035:Pravastatin